← Leaderboards
Christine Sekaggya-Wiltshire
Infectious Diseases Institute
$696,260
Attributed
$696,260
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $143.5K · FY2021–25$200K$150K$100K$50K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$696,260 · 1
By mechanism
R01$696,260 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Adult”
- Beth Baseler · Leidos Biomedical Research, Inc.$127,607,354
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$93,592,175
- Susan M Landau · University Of California Berkeley$47,252,026
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$42,295,422
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Evan Z Macosko · Broad Institute, Inc.$32,116,761
Research focus
AdultDrug KineticsAdverse Drug ReactionAdverse EventAcquired Immunodeficiency SyndromeAffectAfricanAlternative TreatmentAnti-Retroviral AgentsAuthorityAdverse Drug EffectBody Weight DecreasedCategoriesCessation Of LifeChildClinical PredictorsClinical TrialsCohortCohort StudiesCollaborationsCoughingCountryCytochromesEnrollment
Grant awards (5)
Clinical Predictors of weekly Rifapentine/isoniazid related adverse drug reactions during national roll-out of tuberculosis preventive therapy$143,543
R01 · FY2025 · AI · contact PI
Clinical Predictors of weekly Rifapentine/isoniazid related adverse drug reactions during national roll-out of tuberculosis preventive therapy$140,663
R01 · FY2024 · AI · contact PI
Clinical Predictors of weekly Rifapentine/isoniazid related adverse drug reactions during national roll-out of tuberculosis preventive therapy$137,730
R01 · FY2023 · AI · contact PI
Clinical Predictors of weekly Rifapentine/isoniazid related adverse drug reactions during national roll-out of tuberculosis preventive therapy$135,954
R01 · FY2022 · AI · contact PI
Clinical Predictors of weekly Rifapentine/isoniazid related adverse drug reactions during national roll-out of tuberculosis preventive therapy$138,370
R01 · FY2021 · AI · contact PI